Colorectal cancer ranks as the third most prevalent cancer among both men and women in the United States, and alarmingly, its incidence is rising among individuals under the age of 50, as reported by the National Cancer Institute. In response to this trend, the guidelines for colorectal cancer screening underwent a revision in 2022, stipulating that individuals at average risk for colorectal cancer should commence regular screenings at the age of 45.
Jeannine Pickrell, RN, who serves as the Director of Disease Management & Population Health at the Defense Health Agency, emphasizes the critical importance of regular screenings in early detection, when colorectal cancer is most treatable. Given the escalating rates of colorectal cancer in younger demographics, initiating screening at 45 becomes imperative.
Under TRICARE, several options for colorectal cancer exams are covered. These routine screenings are recommended for individuals at average risk, starting at age 45. However, for those deemed at increased risk due to factors such as inflammatory bowel disease, personal or family history of colorectal cancer or polyps, or certain genetic syndromes, screenings may need to commence earlier. Consultation with a healthcare provider can determine the appropriate screening timeline and methods tailored to individual risk profiles.
A variety of colorectal cancer exams are available, ranging from colonoscopies to stool tests. Some stool tests can even be conducted at home using a kit to collect a sample, which is then sent to a lab for analysis. TRICARE covers several common tests for individuals at average risk, including fecal occult blood testing, fecal immunochemical testing (FIT), flexible sigmoidoscopy, CT colonoscopies, and conventional colonoscopies, each with recommended screening intervals.
In the event of a positive or abnormal result on certain tests, such as FIT or a CT colonoscopy, further evaluation via a conventional colonoscopy may be necessary to confirm findings.
For individuals unsure about the most suitable screening method, consulting with their provider during a Health Promotion and Disease Prevention Exam can provide clarity.
Screening costs are contingent upon the type of screening received and whether it occurs during a preventive care visit or specialty care outpatient visit. Utilizing the TRICARE Compare Cost Tool can help determine individual costs for these visits.
